0001140361-26-009247
SEC filingOpus Genetics, Inc. reported a net loss of $49.6 million for fiscal year 2025, an improvement from a net loss of $57.5 million in the prior year. The company generated $14.2 million in license and collaborations revenue, primarily from its Viatris License Agreement, compared to $11.0 million in 2024. Total operating expenses were $52.8 million, down from $73.1 million in 2024, which included a $28.0 million charge for acquired in-process research and development related to the Opus Acquisition. The net loss per share was $0.80, improved from $2.15 in the prior year. The company ended the year with $45.1 million in cash and cash equivalents, bolstered by $50.0 million in net cash provided by financing activities, including equity offerings. The forward-looking significance centers on advancing its clinical-stage gene therapy pipeline, including OPGx-LCA5 and OPGx-BEST1, with key clinical data readouts and regulatory interactions planned.
Opus Genetics reported a net loss of $49.6 million for the fiscal year ended December 31, 2025, representing an improvement from a net loss of $57.5 million in the prior year. This 13.8% reduction in net loss was driven by a $20.3 million decrease in total operating expenses, partially offset by a $3.2 million increase in revenue. The company's license and collaborations revenue grew to $14.2 million from $11.0 million in 2024, primarily attributable to the Viatris License Agreement. Operating expenses declined to $52.8 million from $73.1 million, largely due to the absence of the $28.0 million acquired in-process research and development expense recorded in 2024 related to the Opus Acquisition. Research and development expenses increased to $30.8 million from $26.9 million as the company advanced its clinical programs, while general and administrative expenses rose to $22.0 million from $18.2 million.
Revenue for FY2025 consisted entirely of $14.2 million in license and collaborations revenue, representing a 29.1% increase from the $11.0 million reported in FY2024. This revenue is primarily derived from the Viatris License Agreement for Phentolamine Ophthalmic Solution 0.75% (PS), which includes reimbursement for development costs and royalties. The company recognized $10 million in milestone payments following FDA approval of RYZUMVI® for pharmacologically induced mydriasis in September 2023, with additional potential payments of up to $130 million upon achieving specified regulatory or net sales milestones. The company's gene therapy programs have not yet generated commercial revenue but represent the primary long-term growth opportunity.
The company reported a loss from operations of $38.6 million in FY2025, improved from a loss of $62.1 million in the prior year. This improvement was primarily due to the reduction in operating expenses, as revenue growth was offset by increased R&D investment. The company's cost structure remains heavily weighted toward research and development, which accounted for 58.3% of total operating expenses. General and administrative expenses represented 41.6% of operating expenses. The company has no gross profit margin as it does not manufacture or sell products directly; all revenue comes from licensing and collaboration agreements. Operating margin improved to -272% from -565% in the prior year, reflecting both revenue growth and expense management.
The company used $35.3 million in cash for operating activities during FY2025, compared to $25.6 million in the prior year. This increase in cash usage was primarily due to the timing of working capital changes. The company generated $50.0 million in net cash from financing activities through equity offerings, including a $23.0 million registered direct offering in November 2025 and $21.5 million from March 2025 financings. As of December 31, 2025, the company had $45.1 million in cash and cash equivalents, $50.0 million in total current assets, and $50.2 million in total assets. Total liabilities were $34.9 million, including $26.0 million in warrant liabilities. Stockholders' equity was $15.3 million, with an accumulated deficit of $188.6 million.
The company's strategic focus is on advancing its clinical-stage gene therapy pipeline, particularly OPGx-LCA5 for LCA5-related inherited retinal disease and OPGx-BEST1 for BEST1-associated retinal disease. Management expects to present Phase 1/2 six-month pediatric cohort data for OPGx-LCA5 in May 2026 and anticipates dosing in the Phase 3 portion of the trial in the second half of 2026. For OPGx-BEST1, three-month results from Cohort 1 are expected mid-year 2026. The company is seeking a strategic partner for its APX3330 diabetic retinopathy program. Key risk factors include dependence on clinical trial success, regulatory approvals, competition, intellectual property protection, and the need for additional financing. The company believes its current cash position will fund operations for at least the next 12 months.